Efficacy of Lenvatinib Therapy for Thyroid Cancer by Pathological Type: A Retrospective Real-world Study
In Vivo · 2025
DOI: 10.21873/invivo.14085 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Mioko Matsuo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; matsuo.mioko.202@m.kyushu-u.ac.jp. Hauptthemen laut MEDLINE: Phenylurea Compounds, Thyroid Neoplasms, Quinolines, Antineoplastic Agents. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Refractory differentiated thyroid carcinoma (DTC) and anaplastic thyroid carcinoma (ATC) are associated with poor prognoses. Molecularly targeted agents such as lenvatinib are expected to significantly improve outcomes. However, data from real-world settings remain limited. PATIENTS AND METHODS: A retrospective analysis was conducted in 48 patients with thyroid carcinoma treated with lenvatinib at Kyushu University Hospital between April 2015 and October 2024. We compared overall survival (from time of treatment initiation to death, censoring, or data cutoff) and progression-free survival (from time of treatment initiation to tumor progression as confirmed by image examination) using Kaplan-Meier analysis. A subgroup analysis was also conducted for patients who had and had not received prior radioactive iodine (RAI) therapy. RESULTS: The analysis included 29 female and 19 male cases. The histologic types were papillary thyroid carcinoma in 26 patients, follicular thyroid carcinoma in seven patients, and ATC in 15 patients. Of 33 DTC cases, RAI was not administered in nine cases. The median progression-free survival was 30 months for papillary thyroid carcinoma, 18 months for follicular thyroid carcinoma, and four months for ATC. The median progression-free survival for patients with DTC who received RAI therapy was 19 months, whereas that for patients with DTC without RAI therapy was 46 months. No significant difference was found between the two groups (p=0.243). CONCLUSION: Lenvatinib may be effective in patients with DTC in whom RAI treatment is not feasible in real-world settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; matsuo.mioko.202@m.kyushu-u.ac.jp.
- Department of Hematology, Oncology and Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Zitieren
APA
Matsuo, M., Ito, M., Tsuchihashi, K., Ohmura, H., Hashimoto, K., Kogo, R., Sato, M., Masuda, S., & Nakagawa, T. (2025). Efficacy of Lenvatinib Therapy for Thyroid Cancer by Pathological Type: A Retrospective Real-world Study. In Vivo. https://doi.org/10.21873/invivo.14085
Vancouver
Matsuo M, Ito M, Tsuchihashi K, Ohmura H, Hashimoto K, Kogo R, et al. Efficacy of Lenvatinib Therapy for Thyroid Cancer by Pathological Type: A Retrospective Real-world Study. In Vivo. 2025. doi:10.21873/invivo.14085
BibTeX
@article{Matsuo2025,
author = {Matsuo, Mioko and Ito, Mamoru and Tsuchihashi, Kenji and Ohmura, Hirofumi and Hashimoto, Kazuki and Kogo, Ryunosuke and Sato, Masanobu and Masuda, Shogo and Nakagawa, Takashi},
title = {Efficacy of Lenvatinib Therapy for Thyroid Cancer by Pathological Type: A Retrospective Real-world Study},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.14085}
}
EUVIMED